EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Survivin in cardiovascular diseases and its therapeutic potential

Thomas Mousso, Khanh Pham, Rhonda Drewes, Sefunmi Babatunde, Jessica Jong, Alanna Krug, Gabrielle Inserra, John Biber, Joseph A Brazzo, Sachin Gupte, Yongho Bae

Vascular Pharmacology · 2025-06 · 159 · 107475

DOI: 10.1016/j.vph.2025.107475 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vascular Pharmacology, 2025-06. Verfasst von Thomas Mousso und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Anatomical Sciences, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA. Hauptthemen laut MEDLINE: Survivin, Cardiovascular Diseases, Cardiovascular System. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Institutes of Health, National Heart Lung and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aberrant changes in cell behaviors, such as proliferation, apoptosis, and migration, are some of the contributing factors to the development of various cardiovascular diseases (CVDs) and pathologies, including atherosclerosis, neointimal hyperplasia, and heart failure. In recent years, numerous studies have identified survivin, a key player in the anti-apoptotic pathway, to be extensively involved in modulating cellular functioning in cancer, with many reaching clinical trials. Though seemingly different, CVDs and cancer share abundant similarities regarding abnormal cell modifications and behaviors. This overlap has sparked growing interest in investigating survivin as a therapeutic target in the context of CVD. With new findings emerging rapidly, a comprehensive understanding of survivin's role in cardiovascular pathology is crucial to revealing its full therapeutic potential and translating these discoveries into effective treatments. This review discusses recent findings of survivin in CVDs and related pathologies, focusing on its dual role in promoting proliferation and inhibiting apoptosis, specifically in atherosclerosis, neointimal hyperplasia, stroke, hypertension, myocardial infarction, and heart failure. Across different cell types and pathological contexts, survivin plays a pivotal role throughout the disease progression-from the onset of disease development to the facilitation of compensatory mechanisms post-injury-primarily through its function in regulating cell proliferation and apoptosis. Furthermore, given the limited research on survivin as a therapeutic target for CVDs, potential clinical avenues, including YM155 (a survivin inhibitor) or adenoviral, adeno-associated, and lentiviral vectors, are also discussed. Overall, this review highlights survivin as a promising target for mitigating the detrimental effects of CVDs and to provide new perspectives to advance research on the intervention of CVDs and associated pathologies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SurvivinCardiovascular DiseasesCardiovascular SystemHumansAnimalsApoptosisSignal TransductionCell ProliferationMolecular Targeted Therapy

Stichwörter der Autor:innen

ApoptosisAtherosclerosisHeart diseasesHypertensionNeointimal hyperplasiaProliferationStrokeYM155

Substanzen

SurvivinBIRC5 protein, human

Autor:innen und Institutionen

  • Department of Pathology and Anatomical Sciences, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.
  • Department of Biochemistry, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.
  • Department of Pharmacology, New York Medical College, Valhalla, NY, USA.
  • Department of Pathology and Anatomical Sciences, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA; Department of Biomedical Engineering, School of Engineering and Applied Scienc…

Förderung

  • NHLBI NIH HHS
  • National Institutes of Health
  • National Heart Lung and Blood Institute

Zitieren

APA

Mousso, T., Pham, K., Drewes, R., Babatunde, S., Jong, J., Krug, A., Inserra, G., Biber, J., Brazzo, J. A., Gupte, S., & Bae, Y. (2025). Survivin in cardiovascular diseases and its therapeutic potential. Vascular Pharmacology, 159, 107475. https://doi.org/10.1016/j.vph.2025.107475

Vancouver

Mousso T, Pham K, Drewes R, Babatunde S, Jong J, Krug A, et al. Survivin in cardiovascular diseases and its therapeutic potential. Vascular Pharmacology. 2025;159:107475. doi:10.1016/j.vph.2025.107475

BibTeX
@article{Mousso2025,
  author = {Mousso, Thomas and Pham, Khanh and Drewes, Rhonda and Babatunde, Sefunmi and Jong, Jessica and Krug, Alanna and Inserra, Gabrielle and Biber, John and Brazzo, Joseph A and Gupte, Sachin and Bae, Yongho},
  title = {Survivin in cardiovascular diseases and its therapeutic potential},
  journal = {Vascular Pharmacology},
  year = {2025},
  volume = {159},
  pages = {107475},
  doi = {10.1016/j.vph.2025.107475}
}
Kostenlos starten →